Complement inhibition in neuromyelitis optica spectrum disorder and refractory generalized myasthenia gravis*

From trials to real-world clinical practice

12:15–13:15 CEST
Sunday 20 June 2021

Registered delegates will be able to join the symposium via the EAN platform at www.ean.org/congress2021

PROGRAM

12:15–12:20 Welcome and introduction
Professor Sven Meuth (Germany)

12:20–12:30 Scientific innovation connected through complement
Professor Sven Meuth (Germany)

12:30–12:45 A complementary approach to patient care in AQP4+ neuromyelitis optica spectrum disorder
Professor Orhan Aktas (Germany)

12:45–13:00 Applying the science of complement inhibition in refractory AChR+ generalized myasthenia gravis
Professor Amelia Evoli (Italy)

13:00–13:15 Panel discussion, audience questions and close
All

*This symposium will focus on data relating to neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease and refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChr) antibody-positive.